Tuesday, December 02, 2025 8:09:15 AM
Going out at .49 tooHigh risk going out of business bankrupt
Recent SGMO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:37:29 PM
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market • GlobeNewswire Inc. • 04/29/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:01:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:35:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/04/2026 01:31:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:07:22 PM
- Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering • GlobeNewswire Inc. • 02/03/2026 02:10:43 PM
